# A Study Evaluating the Pharmacokinetics of Doravirine (MK-1439) in Participants With Severe Renal Impairment (MK-1439-051)

> **NCT02641067** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 16 (actual)

## Conditions studied

- Renal Impairment

## Interventions

- **DRUG:** Doravirine

## Key facts

- **NCT ID:** NCT02641067
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01-26
- **Primary completion:** 2016-05-14
- **Final completion:** 2016-05-25
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2019-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02641067

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02641067, "A Study Evaluating the Pharmacokinetics of Doravirine (MK-1439) in Participants With Severe Renal Impairment (MK-1439-051)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02641067. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*